National Institutes of Health (NIH) funding opportunities that may be of interest to University of Illinois Cancer Center members.
Building Sustainable Software Tools for Open Science (R03 Clinical Trial Not Allowed)
- Application Dates: 12/04/25
- Application Date: 01/10/25
- Letter of Intent: NA
- Purpose: The purpose of this Notice of Funding Opportunity (NOFO) is to support research training activities in minority health and health disparities research for individuals from diverse backgrounds, which may include, for example, individuals from groups underrepresented in biomedical, behavioral, clinical and social sciences research based at domestic institutions. Research training experiences would be at domestic institutions and/or at specified international low and middle income country (LMIC) locations for eligible undergraduate students, postbaccalaureate students, graduate students, clinical residents, research fellows, and postdoctoral trainees.
- Application Date: 02/05/25, 06/05/25, 10/05/25
- Letter of Intent: NA
- Purpose: The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this R01 to solicit applications to address barriers and facilitators that impede use or uptake of cancer screening and preventive services in populations that experience health disparities. Interventions should include screening, preventive services, or other healthcare processes, including timely follow-up of abnormal findings, and referral to accessible care. Projects are encouraged to leverage collaborations with community partners and service providers. Interventions should address barriers and facilitators at two or more of the following levels: patient, clinician, healthcare setting, and neighborhood/community. Specific research interests of participating NIH ICs are detailed within. This Notice of Funding Opportunity (NOFO) requires a Plan for Enhancing Diverse Perspectives (PEDP).
- Application Date: Open – See Opportunity
- Purpose: The NIH and the Centers for Disease Control and Prevention (CDC) hereby notify Small Business Concerns (SBCs) whose research is supported by Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants that funds are available for administrative supplements to enhance the diversity of the research and entrepreneurial workforce by recruiting, mentoring, and supporting students, postdoctoral scholars, and eligible investigators from diverse backgrounds, including those from groups that have been shown to be underrepresented in health-related research or in the SBIR and STTR programs. This supplement opportunity is also available to support PD(s)/PI(s) of research grants who are or become disabled and need additional support to accommodate their disability in order to continue to work on the research project. The activities proposed in the supplement application must fall within the scope of the parent grant, and simultaneously advance the objectives of the parent grant and support the research training and professional development of the supplement candidate.
- This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this NOFO are permitted to propose research experience in a clinical trial led by a mentor or co-mentor.
Application Date: 02/02/25, 06/05/25, 10/05/25
Purpose: The purpose of this initiative is to advance the science and implementation of innovative multi-level health care research for older adults from populations that experience health disparities. The initiative will support research designed to (1) gain a better understanding of appropriate screening, diagnostic, and clinical care guidelines in a primary care setting, (2) explore shared decision-making that is needed to enhance care planning and patient agency between clinicians and care teams with the older adult and their caregiver(s), and (3) identify effective strategies for care coordination.
- Underrepresentation of older adults, especially those over the age of 75, in clinical research.
- Age-dependent variations in sensitivity and/or specificity of screening and/or diagnostic tests.
- Screening tests for which diagnostic and/or treatment benefit is unclear after a certain age, or within the context of health status, quality of life, and/or projected life expectancy.
- Screening tests recommendations that consider patient preferences and weigh benefits versus risks/ harms.
- Symptoms and signs that are different from the clinical profiles observed in younger populations.
- Delayed recognition of health conditions by patients and caregivers/family members due to attribution of symptoms as part of the normal aging process.
- Family dynamics, built environment, and sociocultural environment factors that influence optimal care and quality of life.
- Diagnostic protocols or guidelines that create gaps in care delivery.
- Diagnostic, treatment, and continuity of care complexities associated with multiple coexisting chronic conditions.
- Side effects and adverse events associated with complex pharmacological therapy.
- Unfamiliarity or lack of proficiency in key cultural factors across different levels in the healthcare continuum and across various stages of the aging continuum.
- Limited health system resources and infrastructure, and health care policies that may limit coverage eligibility or access to optimal care and health equity.
- Lack of shared decision-making that is guided by principles of aging with dignity, self-determination, and autonomy.
- Application Date: 02/21/25; 06/20/25
- Letter of Intent: Letters of intent are requested, but not required, 30 days before the application due date.
- Purpose: Through The purpose of this notice of funding opportunity (NOFO) is to support rigorous development and validation of Digital Health Technology (DHT) derived biomarkers or clinical outcome assessments (COAs) for remote monitoring to fill a defined unmet clinical endpoint for interventional clinical trials. To increase standardization and improve clinical adoption, applicants must propose to develop and evaluate the DHT enabled biomarkers or COAs in three or more diseases or conditions. Applicants must also propose to conduct development studies that are informed by people with lived experience (PWLE) and patient advocacy organizations. The first phase of this funding mechanism is to evaluate the technical performance of the proposed DHTs with PWLE input; the second phase is to support a prospective longitudinal clinical study in representative populations to validate the DHT. Research outcomes should include demonstrating how a meaningful change in the biomarkers or COAs derived from the DHT(s) can be statistically measured and quantified at the individual participant level.
Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R01 Clinical Trial Optional)
- Application Date: 02/05/25; 06/05/25; 10/05/25
- Letter of Intent: NA
- The purpose of this notice of funding opportunity (NOFO) is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention.
Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional)
- Application Date: 02/16/25; 06/16/25; 10/16/25
- Letter of Intent: NA
- Purpose: The purpose of this notice of funding opportunity (NOFO) is to support policy research projects that examine new or adapted policies pertaining to tobacco, alcohol, and/or cannabis in the U.S., with a particular focus on how the policy or policies influence tobacco, alcohol, and cannabis use or secondhand exposure among populations experiencing disparities. Funded projects will involve authentic engagement with one or more community organizations with the aim of promoting equity in cancer prevention by addressing tobacco, alcohol, and cannabis use and exposure. The long-term goal is to support tobacco, alcohol, and cannabis policy research studies that will improve health equity and promote cancer prevention.
- Application Date: 02/05/25; 06/05/25
- Letter of Intent: NA
- Purpose: The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should be interdisciplinary drawing from the natural and social sciences, account for interdependencies across scales of biological, social, and ecological organization, and make extensive use of theory, modeling, and validation with available large-scale datasets.
- Application Date: 02/05/25; 06/05/25
- Letter of Intent: NA
- Purpose: The goal of this NOFO is to support applications for novel theory and methods development that enable better understanding of how genetic and non-genetic factors contribute to complex trait variation across individuals, families, and populations. Approaches should account for interdependencies across scales of biological, social, and ecological organization, make extensive use of theory, modeling, and validation with available large-scale datasets, and may be interdisciplinary drawing from the natural and social sciences.
Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
- Application Date: 02/16/25; 06/16/25; 10/16/25
- Letter of Intent: 30 days prior to application
- Purpose: The purpose of this Notice of Funding Opportunity (NOFO) is to support studies that will identify, develop, and/or test strategies for overcoming barriers to the adoption, adaptation, integration, sustainability, scale-up, and spread of evidence-based interventions, practices, programs, tools, treatments, guidelines, and policies (herein referred to collectively as evidence-based interventions). Studies that promote equitable dissemination and implementation of evidence-based interventions among underrepresented communities are encouraged. Conversely, there is a benefit in understanding circumstances that create a need to stop or reduce (de-implement) the use of practices that are ineffective, unproven, low-value, or harmful. In addition, studies to advance dissemination and implementation research methods and measures are encouraged. Applications that focus on re-implementation of evidence-based health services that may be disrupted amidst disasters (e.g., pandemics, climate change) remain relevant.
Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
- Application Date: 02/02/25 & 02/02/26
- Letter of Intent: 30 days prior to application due date
- Purpose: The purpose of this notice of funding opportunity (NOFO) is to support highly innovative mechanistic research to accelerate the development of effective precision probiotic interventions. The NOFO aims to identify, understand, and develop strategies to address barriers in precision probiotic interventions’ development to account for human heterogeneity resulting in inconsistent responses to probiotic treatments. Specifically, this NOFO solicits R33 applications that will assess the causality of person-specific features or patterns affecting probiotic responses and identify subgroups of probiotic responders in order to enhance therapeutic outcomes. This NOFO is intended to support projects where potential host biological patterns that are correlated with probiotic usage or interventions have been identified, as demonstrated with supportive preliminary data, which require further mechanistic studies to test for causality. This NOFO will not support efficacy or effectiveness clinical trials.
High-End Instrumentation (HEI) Grant Program (S10 Clinical Trial Not Allowed)
Application Date: 06/02/25; 06/01/26
Letter of Intent: NA
Purpose: The High-End Instrumentation (HEI) Grant Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-end, specialized, commercially available instruments or integrated systems. The minimum award is $750,001. There is no maximum price limit for the instrument; however, the maximum award is $2,000,000. Instruments supported include, but are not limited to, nuclear magnetic resonance spectrometers, X-ray diffractometers, mass spectrometers, high throughput robotic screening systems, DNA and protein sequencers, biosensors, electron and light microscopes, flow cytometers, and biomedical imagers.
Shared Instrumentation Grant (SIG) Program (S10 Clinical Trial Not Allowed)
Application Date: 06/02/25; 06/01/26
Letter of Intent: NA
Purpose: The Shared Instrument Grant (SIG) Program encourages applications from groups of NIH-supported investigators to purchase or upgrade a single item of high-priced, specialized, commercially available instruments or integrated instrumentation system. The minimum award is $50,000. There is no maximum price limit for the instrument; however, the maximum award is $750,000. Instruments supported include, but are not limited to: light microscopes, biomedical imagers, mass spectrometers, nuclear magnetic resonance spectrometers, flow cytometers, DNA and protein sequencers, biosensors, and X-ray diffractometers.
Application Dates: 09/25/25
Other funding opportunities and resources to search for funding are available on our website.